Bronchial Neoplasms Clinical Trial
Official title:
Fraxinus- Assessment of an Open Source Virtual Bronchoscopic Navigation System
NCT number | NCT03745859 |
Other study ID # | 2018/302 |
Secondary ID | |
Status | Suspended |
Phase | |
First received | |
Last updated | |
Start date | November 19, 2018 |
Est. completion date | October 2023 |
Verified date | December 2022 |
Source | Norwegian University of Science and Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To evaluate the feasibility of the Fraxinus Virtual Bronchoscope Navigation (VBN) System in the bronchoscopic access to target lesions. The study emphasizes the system´s efficacy in diagnostics of peripheral pulmonary lesions and the ease of use for the operator.
Status | Suspended |
Enrollment | 40 |
Est. completion date | October 2023 |
Est. primary completion date | October 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - referred to thoracic department in any of the participating hospitals with undiagnosed peripheral pulmonary lesion(s) not visible by bronchoscopy - voluntary signed an informed consent Exclusion Criteria: - pregnancy - Any patient that the Investigator feels is not appropriate for this study for any reason |
Country | Name | City | State |
---|---|---|---|
Norway | St Olavs Hospital | Trondheim |
Lead Sponsor | Collaborator |
---|---|
Norwegian University of Science and Technology | SINTEF Health Research, St. Olavs Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evidence if the Fraxinus VBN System has a role in the assessment of peripheral pulmonary lesions | The proportion of cases in which the use of the system is considered beneficial | 48 hours | |
Secondary | Diagnostic yield | Diagnostic success defined as cytology or biopsy with pathology | 1 week | |
Secondary | Duration of procedure | Time spent with preparations and bronchoscopy | 48 hours | |
Secondary | Adverse events | Procedure related adverse events or unexpected incidents registrated | 48 hours | |
Secondary | Operators-reported satisfaction | Enquiry on main operator´s experience after end of bronchoscopy | 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02493023 -
Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS
|
N/A | |
Terminated |
NCT02050724 -
ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT
|
Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Recruiting |
NCT02804100 -
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
|
N/A | |
Active, not recruiting |
NCT05241873 -
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04862780 -
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376084 -
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
|
||
Recruiting |
NCT03402048 -
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
|
Phase 3 | |
Recruiting |
NCT02264210 -
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
|
Phase 2 | |
Terminated |
NCT05153408 -
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
|
Phase 1 | |
Completed |
NCT01261585 -
Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
|
N/A | |
Recruiting |
NCT06177925 -
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
|
Phase 2 | |
Completed |
NCT02897778 -
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03516214 -
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
|
Phase 1 | |
Completed |
NCT02745002 -
Navigated EBUS and Functional Imaging in Lung Cancer
|
N/A |